Lead Sponsor

Pfizer

Collaborators

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

No

•Men or women between ≥18 and ≤70 years of age at the time of informed consent
•Moderate-to-severe alopecia areata as assessed by a SALT score of ≥25 and \<95 at Screening and Day 1/Baseline.
•Current episode of hair loss for ≥6 months but \<5 years
•Stable disease condition (no significant growth of hair) in the last 6 months as assessed by the Investigator
•Willing to keep the same hair style and color (eg, hair products, process, and timing for hair appointments) for the duration of the study

•History of male or female pattern hair loss \>Hamilton stage III or \>Ludwig stage II
•Other types of alopecia (eg, cicatricial/scarring alopecia \[including central centrifugal cicatricial alopecia\], traction alopecia, or telogen effluvium) or other diseases that could cause hair loss
•Active scalp inflammation, scalp infection, scalp psoriasis, or any other scalp condition that may interfere with the SALT assessment
•Previous use of Janus kinase (JAK) inhibitor (oral or topical), including participation in clinical studies of JAK inhibitors

Related studies

NCT07029711 · Severe Alopecia Areata

NCT06826196 · Alopecia Areata (AA)

NCT06562270 · Alopecia Areata

NCT07133308 · Alopecia Areata

NCT06327581 · Alopecia Areata

Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia Areata